Pharmacopeia

CWP-0163

METOCLOPRAMIDE

Gastrointestinal · Gastrointestinal · Level 3

Core pharmacology

Class Group

Anti-emetic

Dopamine Antagonist

Legacy Cicm Level

Level 3

Indications Uses

1. Prokinetic
2. Antiemetic
3. Migraine
4. Reflux oesophagitis

Presentation

PO/IV

Physiological effects

CVS: Hypotension after IV; Dysrhythmias and QTc

GIT
1. Selective stimulation of gastric muscarinic receptors
- Coordinated GIT contraction (accelerates gastric emptying)
- Increased amplitude and frequency of Longitudinal muscle contraction
- Lowers threshold for peristaltic reflex to occur
2. Direct action on smooth muscle to increase tone (including increased LOS)
3. Reduces intestinal muscle fatigue

CNS
- Neuroleptic effects
- Extrapyramidal effects
- Increase prolactin

GU- Increased uterine peristalsis

Protein binding

20% PB

Gastrointestinal · Gastrointestinal

Introduction

Benzamide D2-R antagonist

Mechanism of action

1. Decreased sensitivity of visceral afferents to vomit center
2. Central D2 blockade increased threshold at CTZ
3. Selective GIT muscarinic effects leading to prokinesis
4. Other effects:
- Inhibition of 5-HT3
- Anti-H1 effects

Adverse Effects Toxicity

1. EPS
2. Dizziness
3. NMS
4. QTc prolongation

Absorption

Rapid oral absorption with variable BA (30-90%) due to first pass conjugation

Volume of distribution

Vd 2-3L/Kg

Metabolism

Hepatic metabolism to sulfate conjugate

Excretion

80% renally excreted (20% of this is unchanged)

Half-life

T1/2= 2.5-5 hours

Introduction

Dopamine Antagonist

Mechanism of action

1. Antagonism of peripheral D2 receptors
2. Selective stimulation of gastric muscarinic receptors
- Coordinated GIT contraction
- Increased amplitude and frequency of Longitudinal muscle contraction
- Lowers threshold for peristaltic reflex to occur
3. Direct action on smooth muscle to increase tone (including increased LOS)
4. Reduces intestinal muscle fatigue
5. Decreased sensitivity of visceral afferents to vomit center
6. Central D2 blockade increased threshold at CTZ

Adverse Effects Toxicity

1. Drowsiness, dizziness and fainting
2. EPS- including oculogyric crises
3. Neuroleptic malignant syndrome
4. QTc prolongation and conduction abnormalities
5. Abdominal cramping
6. Hyperprolactinaemia
7. Hypertension in phaeochromocytoma

Absorption

Rapidly absorbed with variable F (30-100%) due to First pass metabolism

Volume of distribution

Vd 2-3.5L/kg

Metabolism

Hepatic sulfate conjugation
Excretion

Excretion

80% renally excreted, 20% of this unchanged

Half-life

T1/2= 2-5 hours